Skip to main content
Clinical Trials/NCT02086019
NCT02086019
Completed
Not Applicable

A Prospective Randomised Controlled Trial

Brighton and Sussex University Hospitals NHS Trust1 site in 1 country250 target enrollmentMay 1, 2014

Overview

Phase
Not Applicable
Intervention
Conservative Arm
Conditions
Acute Coronary Syndromes
Sponsor
Brighton and Sussex University Hospitals NHS Trust
Enrollment
250
Locations
1
Primary Endpoint
Death
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

For octogenarian patients with NSTEMI (non-ST segment elevation myocardial infarction) an invasive-guided strategy will prove superior to a conservative strategy with respect to a combined endpoint of all cause mortality and non-fatal myocardial infarction.

Registry
clinicaltrials.gov
Start Date
May 1, 2014
End Date
December 12, 2019
Last Updated
5 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Brighton and Sussex University Hospitals NHS Trust
Responsible Party
Principal Investigator
Principal Investigator

Adam de Belder

Consultant Cardiologist

Brighton and Sussex University Hospitals NHS Trust

Eligibility Criteria

Inclusion Criteria

  • AGE\>80 Non-STEMI - characteristic chest pain accompanied by
  • Typical ischaemic ECG changes
  • A troponin rise
  • Suitable for conservative or invasive strategy

Exclusion Criteria

  • Lack of suitability for whatever clinical reason to be randomised eg dementia, co-morbidity
  • Acute STEMI
  • Cardiogenic shock
  • Platelet count =50 x 109/mm3
  • Patient life expectancy \< 1 year
  • Known allergies to clopidogrel, aspirin, heparin, stainless steel, IV contrast or stent drug elutant
  • Recent major GI haemorrhage (within 3 months)
  • Any previous cerebral bleeding episode
  • Participation in another investigational drug or device study
  • Patient unable to give consent

Arms & Interventions

Conservative Arm- Medical therapy

Medical therapy

Intervention: Conservative Arm

Invasive Arm-angiogram with PCI or CABG

same medical drug therapy as conservative arm, and angiogram with PCI (percutaneous coronary intervention) or CABG (coronary artery bypass grafting) revascularisation if appropriate

Intervention: Invasive Arm

Outcomes

Primary Outcomes

Death

Time Frame: 1 year

The cause of death will be adjudicated as being due to cardiovascular causes, non cardiovascular causes, or undetermined causes. * Cardiovascular Death includes sudden cardiac death, death due to acute myocardial infarction, death due to heart failure or cardiogenic shock, death due to stroke or death due to other cardiovascular causes * Non-Cardiovascular Death is defined as any death not covered by cardiac death or vascular death. * Undetermined cause of death refers to a death not attributable to one of the above categories of cardiovascular death or to a non-cardiovascular cause. N.B For this trial all deaths with undetermined causes will be included in the cardiovascular category.

non-fatal myocardial infarction

Time Frame: 1 year

The ESC/ACC (European Society of Cardiology and the American College of Cardiology) definition of myocardial infarction will be applied, including the special circumstances of same admission myocardial re-infarction, or myocardial infarction peri-PCI.

Secondary Outcomes

  • Major bleeding(1 year)
  • Deterioration of renal function during hospital admission(During index admission)
  • In-hospital major complications(At 3, 6 and 12 months and at 2,3 and 4)
  • Unplanned revascularisation(1 years)
  • Permanent Stroke(1 year)
  • Angina symptoms (3 months; 1yr)(3 months and 1 year)
  • All cause mortality(2,3 and 4 year)
  • Hospital readmission for ACS/STEMI(At 3, 6 and 12 months and at 2,3 and 4 years)
  • Stent thrombosis(1 year)

Study Sites (1)

Loading locations...

Similar Trials